AbbVie scores FDA approval for Parkinson's drug; Novartis wins generics battle over respiratory drug in India;

@FiercePharma: AmerisourceBergen storms into animal health with $2.5B purchase of MWI. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: Off to #JPM15! Picture | Follow @CarlyHFierce

> AbbVie ($ABBV) won FDA approval for its Duopa treatment for patients with advanced Parkinson's disease. Release

> Novartis ($NVS) got a favorable decision on generic sales of its respiratory drug Onbrez, as India's high court ordered Cipla to stop selling its copycat version of the product in the country. More

> Keryx Biopharmaceuticals ($KERX) appointed Chief Operating Officer Greg Madison as the company's chief executive officer, replacing current CEO Ron Bentsur. Release

> Amag Pharmaceuticals ($AMAG) roped in $74 million in Q4 2014 sales and updated its 2015 sales guidance to $355 million--a 300% increase over the previous year. Statement

> Aegerion Pharmaceuticals ($AEGR) wrapped up its acquisition of Myalept, an injection that treats complications of leptin deficiency in patients with generalized lipodystrophy (GLD), or loss of fat tissue under the skin. More

Medical Device News

@FierceMedDev: ICYMI: Qiagen exceeds 2014 placement goals for molecular Dx, hedges its bets on continued success. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: ICYMI: PureTech bumps its early life science funds up to $107M. Article | Follow @StacyALawrence

@EmilyWFierce: Roche shells out $1B plus milestones for a majority share in Foundation Medicine. Release | Follow @EmilyWFierce

> JP Morgan: Qualcomm Ventures, Novartis co-fund joint investment company to tune of $100M. More

> Wright releases positive prelim Q4 and FY 2014 results; progress on Augment. Story

> Swiss researchers develop bendable implant to tap into the spinal cord. Article

Biotech News

@FierceBiotech: $SHPG nabs NPS's rare disease drug portfolio in $5.2B buyout. News | Follow @FierceBiotech

@JohnCFierce: $JNJ steps in with a $509M-plus deal to partner on a tau vaccine for Alzheimer's. Report | Follow @JohnCFierce

@DamianFierce: And so now Roche owns 56% of Foundation Medicine. Story | Follow @DamianFierce

> Mersana lines up for $300M in an R&D deal with Takeda. More

> Bristol-Myers aces a lung cancer trial with its blockbuster in waiting. Story

> Biogen Idec grabs Convergence, neuropathic pain portfolio in $675M buyout. Report

Biotech IT News

> Adaptive buys Sequenta to pool immune sequencing capabilities. Story

> FDA to publish guidance on social media and clinical trial e-consent in 2015. More

> Novartis picks Qualcomm tech to enable remote collection of trial data. Article

> 23andMe strikes $60M Genentech deal to continue pivot to database-driven R&D. Report

> Biogen Idec inks $30M genetic R&D alliance with Columbia University. Item

CRO News

> Evotec extends a biotech deal with $13M on the line. Report

> Quintiles' Novella partners up for cardio device R&D. Story

> PPD's in-house biotech pairs up with J&J. Article

> AMRI spends $60M to beef up its manufacturing heft. More

> WuXi buys big into genomics with NextCODE deal. News

Animal Health News

> New strain of virulent PEDv found on Minnesota hog farm. Article

> Catterton offloads PetVet hospital network to Canadian pension plan for $440M. More

> Petco banishes China-made treats from shelves. Item

> Nexvet plans $60M IPO to advance pipeline of pet therapeutics. Story

> Aratana scores a 'first' with USDA approval for canine lymphoma drug. Report

And Finally… As flu season worsens, the CDC is urging doctors to prescribe antiviral drugs at the first sign of symptoms. Story

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.